Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039269 | 0.88 | KDM4E (0.51) | KDM4EALDH1A1GAAPOLBPDGFRB | |
| SCHEMBL29956595 | 0.88 | KDM4E (0.51) | KDM4EALDH1A1GAAPOLBPDGFRB | |
| SCHEMBL4397800 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1GAAPOLBAXL | |
| SCHEMBL29955116 | 0.84 | HSD17B10 (0.59) | KDM4EALDH1A1GAAPDGFRBPDGFRA | |
| SCHEMBL92643 | 0.79 | AXL (0.59) | KDM4EALDH1A1GAAPOLBAXL | |
| SCHEMBL29953506 | 0.79 | AXL (0.59) | KDM4EALDH1A1GAAPOLBAXL | |
| SCHEMBL4106429 | 0.79 | DAO (0.60) | KDM4EALDH1A1GAAPOLBPDGFRB | |
| SCHEMBL9269640 | 0.79 | AXL (0.64) | KDM4EALDH1A1GAAPOLBAXL | |
| SCHEMBL30293236 | 0.78 | KDM4E (0.61) | KDM4EALDH1A1GAAPOLBAXL | |
| SCHEMBL29955231 | 0.78 | GRIN2D (0.56) | KDM4EALDH1A1GAAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20150094348-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CT CARDIOLOGICO MONZINO S P A (IT) | 2015-04-02 | — | — | US | disclosed |
| US-20150094348-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CT CARDIOLOGICO MONZINO S P A (IT) | 2015-04-02 | — | — | US | disclosed |
| EP-2635275-B1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CT CARDIOLOGICO MONZINO SPA (IT) | 2014-08-06 | — | — | EP | disclosed |
| EP-2635275-B1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CT CARDIOLOGICO MONZINO SPA (IT) | 2014-08-06 | — | — | EP | disclosed |
| US-20140148472-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CENTRO CARDIOLOGICO MONZINO SPA (IT) | 2014-05-29 | — | — | US | disclosed |
| US-20140148472-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CENTRO CARDIOLOGICO MONZINO SPA (IT) | 2014-05-29 | — | — | US | disclosed |
| EP-2635275-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Centro Cardiologico Monzino SpA (IT) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012059869-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059869-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148472-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | GPR65, GPR17, GPR27 | KDM4E 4430/4885ALDH1A1 1322/4885GAA 1627/4885 |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | KDM4E 1593/4885ALDH1A1 554/4885GAA 996/4885 |
| US-20150094348-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | GPR65, GPR17, GPR27 | KDM4E 4430/4885ALDH1A1 1322/4885GAA 1627/4885 |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | KDM4E 3009/4885ALDH1A1 2439/4885GAA 1322/4885 |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | KDM4E 1593/4885ALDH1A1 554/4885GAA 996/4885 |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | KDM4E 438/4885ALDH1A1 200/4885GAA 243/4885 |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH3A, IDH1, IDH2 | KDM4E 1995/4885ALDH1A1 461/4885GAA 2153/4885 |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | KDM4E 1593/4885ALDH1A1 554/4885GAA 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.